BioSpace

Biopharma cuts at manufacturing plants expected to affect 4,000+

As companies invest billions of dollars to reshore manufacturing, 10 biotech and pharma businesses are reportedly trimming ...
24/7 Wall St.

Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher

Moderna stock is surging even after an analyst cited its 636% yearly gain as reason enough to step back, and the real ...
Fintel on MSN

BioNTech SE and Bristol Myers Squibb report phase 2 data for pumitamig in advanced NSCLC

BioNTech SE and Bristol Myers Squibb Company announced first data from the global Phase 2 ROSETTA Lung-107 clinical trial evaluating pumitamig, an investigational PD-L1xVEGF-A bispecific ...

BioNTech (BNTX) Reworks Phase 3 Breast Cancer Trial Around New Combination Approach

BioNTech (NasdaqGS:BNTX) and Gilead Sciences agreed to a clinical trial collaboration to study pumitamig with sacituzumab ...

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy?

BioNTech announced that it was stopping a Phase 2 clinical trial for autogene cevumeran, which it was testing as an adjuvant ...

BioNTech evaluates next steps as breast cancer drug shows limited patient benefit

On Monday, BioNTech SE BNTX and DualityBiologics (Suzhou) Co., Ltd. announced that their Phase 3 DYNASTY-Breast02 trial met ...
Fierce Biotech

BioNTech sees ‘limited’ benefit to ADC after phase 3 reveals modest efficacy, ILD cases

BioNTech has reported modest efficacy and unexpected safety findings in a phase 3 breast cancer trial, leading the company to ...

BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study

The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.
The Manila Times

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

BioNTech SE (Nasdaq: BNTX, 'BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. ('DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase 3 clinical trial (NCT06018337) met ...
RTTNews

BioNTech's BNT113 Misses Progression-Free Survival Endpoint In Phase 3 Head And Neck Cancer Trial

HPV16-positive HNSCC represents a subset of head and neck cancers, and treatment options remain limited for patients with recurrent or metastatic disease. BNT113 received Fast Track Designation from ...
BioSpace

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced a clinical trial collaboration and supply agreement with Gilead ...

BioNTech, DualityBiologics' Late-Stage Trial of Metastatic Breast Cancer Therapy Meets Primary Endpoint; Severe, Fatal Events Reported

BioNTech (BNTX) and DualityBiologics' phase 3 trial of trastuzumab pamirtecan in metastatic breast cancer achieved its primary endpoint of demonstrating a statistically significant improvement in ...